From Site of Care Migration to the Impact of Reimbursement Changes SmartTRAK evaluates market trends to watch for in 2022.
by Gary Delhougne, GM Wound

The Skin Substitute/CTP (Cellular and/or Tissue-based Products) market is undergoing significant growth and change. Reimbursement motives, COVID-19 and clinician site of care decisions had a profound impact on the market in 2020 and 2021. The growth outlook for 2022 remains strong as providers and industry adapt to unique market conditions.

SmartTRAK estimates the 5-year CAGR (compound annual growth rate) through 2025 for Skin Substitutes/CTP products to be in the mid to high single digits. In 2020, industry revenue surpassed $1B and SmartTRAK expects the market to pass $1.5B by 2025.

To better understand the impact of site of care changes, SmartTRAK launched a new subscription module specifically covering site of care changes occurring in the Skin Substitute/CTP market. It’s SmartTRAK’s fastest-growing new product offering and you can learn more by clicking here.

As SmartTRAK looks to 2022, we see three trends to consider for the Skin Substitute/CTP market –

We are pleased to announce that Kris Flinn has joined the team at SmartTRAK as an analyst in Wound Care. Kris has 20+ years of experience within wound care, including Smith & Nephew. Kris recently ran a consultancy focusing on assisting med device companies with commercial strategies. He is based in England.

Meet Kris Finn:

What is your role with SmartTRAK? I’m an analyst within the wound team, with a particular focus on NPWT in Europe.

What do you like about SmartTRAK? The quality of the information and analysis produced is excellent, and something which does not exist anywhere else. All of the team members are true experts in their field, and have the experience and networks to prove it.

What is something special or unique that you bring to SmartTRAK subscribers?

SmartTRAK, the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies, was once again cited as a trusted source, this time in ConvaTec's press release "Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc" published January 28th.

ConvaTec, in the press release, stated that it was " ...

Jointechlabs – Emerging leader in point-of-care regenerative and rejuvenation medicine therapies

Nathan Katz PhD, ALBB, Co-founder, CEO and Chief Technical Officer at Jointechlabs* (JTL) discussed the Company’s unique technology platform and product developments in a recent interview with SmartTRAK.

JTL is a privately-held regenerative medicine solutions company based in North Barrington, IL. As an emerging leader in point-of-care regenerative and rejuvenation medicine therapies, JTL has patented, portable medicine products that enable personalized therapies. The Company’s lead product, MiniTC*, is an FDA-cleared portable medical device for isolation of fragmented and purified fat grafts (microfat) at the point-of-care. Additionally, JTL is developing therapies for unmet medical needs, with its first product candidate, JTL-T-01*, a proprietary injectable stem cell scaffold in clinical development as a biologic therapy for osteoarthritis, for approval under the FDA’s fast-track program.

SmartTRAK: Can you first tell us a little bit about yourself and then about Jointechlabs?

Nathan Katz: I have a medical background. I graduated from medical school back many years ago in Russia, then graduated from Tel Aviv University and acquired my Master’s Degree and PhD in Cell Biology. I came to the US 16 years ago, first, working on genetics and embryonic stem cells. I spent quite a lot of time in research with embryonic stem cells in the first decade of this millennia and then I was looking for the technology that could be translated into applicable medical technology and translated into therapy.

Adult stem cells came up as the first and obvious choice to look at more precisely, so we shifted, and I shifted personally, my focus from embryonic stem cells towards adult stem cells. I came across PadZuke, and Patricia, who published the first publication on actual adipose-derived stem cells in 2001. My idea was that it is the right way to go and could lead to ...

To read the entire interview with Dr. Katz, please click the button below to download the complete transcript.

SmartTRAK is the leading source of competitive intelligence used by the top ten global wound care & orthopedics companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

We are pleased to announce that Tracey Clarke has joined the team at SmartTRAK as our new Account Manager, Customer Success. Tracey has 20+ years experience in the Print and Digital Communications industry, including roles as a Client Relations Manager and IT Project Manager at Broadridge Customer Communications and DST Output LTD.

Meet Tracey Clarke:

What is your role with SmartTRAK? I am an Account Manager on the newly established Customer Success team.

What do you like about SmartTRAK? This is an exciting time to be starting at SmartTRAK. There are many positive changes happening and I am enjoying the opportunity to see the outcome. I feel very fortunate to be with a company that helps others Be the Expert.

Despite the seemingly never-ending COVID-19 epidemic, SmartTRAK continued to keep you informed of everything that transpired in the MedTech industry in 2021. As the leading provider of real-time market data and analysis for the orthopedic, wound, regenerative medicine and neuro therapies markets, SmartTRAK is uniquely suited to make you the expert on all the latest developments. Our knowledgeable analysts covered a lot of ground, everything from breaking medical device event coverage to interviews with some of the industry's top thought leaders.

Here are SmartTRAK's Top 10 blog posts of the past year that garnered the most attention from you and your colleagues, plus 3 bonus posts, because at SmartTRAK we always strive to deliver more than what's expected!

Trends in OrthoBiologics & Regenerative Medicine: A Surgeon's Perspective
by Freddy Buntoum

In this wide-ranging interview with SmartTRAK, Dr. Wasik Ashraf, an Orthopaedic Surgeon specializing in Sports Medicine, gives his view of CMS' FY21 OPPS-ASC Final Rulemaking, and discusses emerging trends and innovation in OrthoBiologics and Regenerative Medicine.

SmartTRAK was cited as a source in a press release from Smith+Nephew* entitled "Smith+Nephew acquires novel cementless partial knee system."

Smith+Nephew, in the release, announced that it has acquired Engage Surgical, owner of the only cementless unicompartmental (partial) knee system commercially available in the US. The article cited SmartTRAK's reporting that "the partial knee market is currently worth approximately $300 million in the US".

The press release goes on to say that "This acquisition strongly supports Smith+Nephew’s strategy for growth by transforming its business through innovation and acquisition, while also providing differentiation for its customers. The Engage Surgical Partial Knee System is a novel, modern cementless knee implant to serve a resurgent segment driven by the potential for better long-term fixation through biologic integration, shorter operating times, and the shift to Ambulatory Surgery Centers (ASCs)."

Randy Kilburn, Exec VP & GM, Reconstruction, Robotics and Digital, added:

“Smith+Nephew is now the only medical device company offering both cemented and cementless partial knee implants in the US, as well as robotics-assistance through the CORISurgical System that is well-suited for the precise alignment needed .... The acquisition will drive Smith+Nephew’s Robotics and Real Intelligence strategy. Partial knee procedures are well-matched for robotics due to the need for precise alignment and Smith+Nephew’s CORI Surgical System already supports the cemented JOURNEY II^◊ unicompartmental knee. The Engage Surgical Partial Knee System is optimised for robotics and will have an application with CORI in the future. Engage Surgical’s Partial Knee System also complements Smith+Nephew’s focus on serving the growing outpatient market, with an increasing proportion of knee procedures performed in ASCs."

Used by the leading orthopedic and wound care companies, SmartTRAK is the premier provider of competitive intelligence, including market data, analysis and advisory services for the orthopedic, wound, regenerative medicine and neuro therapies markets. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click the button below.

We are pleased to announce that Courtney Sheedy has joined the team at SmartTRAK as our new General Manager, Spine. Courtney has 15+ years of Global Marketing and Product Development experience dedicated to the spinal medical device market serving in leadership roles for companies like Zimmer Biomet, Alphatec, Corelink and joimax.

Meet Courtney Sheedy:

What is your role with SmartTRAK? General Manager, Spine

What do you like about SmartTRAK? I’m fortunate to have been a user of SmartTRAK for many years prior to joining the ranks as a GM. I love how dynamic the SmartTRAK platform is. For Marketing and Business Development teams to be able to access real-time market information to guide their pipeline planning and day-to-day marketing strategies is one of the most unique and beneficial attributes. I also love how user-friendly the platform is. As a former marketer, I loved the ability to export data files for direct use.

The Spine Market was down in every category as Covid halted elective spine cases globally. 

Spine market performance in Q321 was mired by the resurgence of the Covid-19 Delta Variant, both in the US and OUS. All markets were down sequentially YoY, with dynamic devices taking more than a double digit hit globally.

Globus’ potential takeover of Nuvasive was the biggest storyline of Q3, as they search to gain market share through acquisitions. Market participants are certainly taking note of Globus, as Medtronic CEO Geoffrey Martha stated they are trying to attract Globus users with the launch of their Catalyft Expandable Interbody System.

Among the many topics covered in detail in our comprehensive Q321 Spine Market Recap* are:

In an interview with SmartTRAK, Mesh Suture, Inc. (MSI) Founder Gregory Dumanian MD, discusses the Company and its novel suturable mesh that has the potential to change how hernias and other conditions are treated.

MSI is commercializing a novel suturable mesh that combines a mesh’s ability to distribute forces and support tissue with the precise placement and minimal foreign body presence of a suture. In a time when patients and physicians are rethinking how mesh is used in hernia treatment, MSI’s Duramesh offers the potential of retaining the durability of mesh repair with less foreign body presence. Today, the Company is running clinical trials and building evidence to support regulatory clearance in the United States. To find out more about the Company and its operation, SmartTRAK talked with Gregory Dumanian, MD, Chief of Plastic Surgery at Northwestern University’s Feinberg School of Medicine, Founder & Medical Officer of MSI and the inventor of the new technology.

Click on the following video to listen to SmartTRAK Senior Analyst Doug Devens’ interview with Dr. Dumanian, which was recorded via Zoom audio (24: 35 min). A link to download a complete transcript of the interview is also provided below.